D'Mum,
Thanks for your views - I do appreciate them. I guess I was referring to the way in which BT kept the market fully informed (and is still doing so) - almost to the detriment of the AVM SP.
But...the mkt was informed. And he did it to a timetable. When we have so little to go on (re:AIM), except my hard crusty crystal balls, it really is somewhat of leap of faith for us punters to invest in this.
All I read about on theis forum is the way in which MF and his cornes have slipped up. You and possibly a few other kind souls are the only ones to see a more positive element. Certainly I agree with the fundamentals...but let's be honest, I think all of us are a little suspicious of this coming off.
I am quite a small holder (hence my crusty ones) and fully appreciate all of these postings. I do not have much to lose at all and am using AIM as a learning experience, perhaps in the same way you learnt about AVM?
I am clutching the small hard ones and look forward to my full learnings (lol)
- Forums
- ASX - By Stock
- hey marc
D'Mum,Thanks for your views - I do appreciate them. I guess I...
-
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AIM (ASX) to my watchlist
|
|||||
Last
39.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $82.48M |
Open | High | Low | Value | Volume |
40.0¢ | 40.0¢ | 38.5¢ | $24.68K | 62.72K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 35851 | 38.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
39.5¢ | 14255 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 35851 | 0.385 |
1 | 21911 | 0.380 |
1 | 5000 | 0.370 |
1 | 15000 | 0.360 |
1 | 20000 | 0.355 |
Price($) | Vol. | No. |
---|---|---|
0.395 | 14255 | 1 |
0.400 | 15880 | 1 |
0.410 | 5128 | 1 |
0.415 | 6000 | 1 |
0.420 | 30962 | 1 |
Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
Featured News
NEWS
Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo
NEU
Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
AIM (ASX) Chart |